Contemporary Management of ST-Segment Elevation Myocardial Infarction

References

• . Roger VL, Go AS, Lloyd-Jones DM, . Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18–e209
   PubMed Web of Science ®Google Scholar
• . Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007;28(20):2525–2538
   PubMed Web of Science ®Google Scholar
• . Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104(4):503–516
   PubMed Web of Science ®Google Scholar
• . Van de Werf F, Bax J, Betriu A, . Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29(23):2909–2945
   PubMed Web of Science ®Google Scholar
• . de Lamos JA, Antman EM, Giugliano RP, . ST-Segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. Am J Cardiol. 2000;85(3):299–304
   PubMedGoogle Scholar
• . Boersma E, Mercado N, Poldermans D, Gardien M, Vos J, Simoons ML. Acute myocardial infarction. Lancet. 2003;361(9360):847–858
   PubMedGoogle Scholar
• . Rovelli F, De Vita C, Feruglio GA, Lotto A, Selvini A, Tognoni G. GISSI trial: early results and late follow-up. Gruppo Italiano per 1a Sperimentazione della Streptochinasi nell'Infarto Miocardico. J Am Coll Cardiol. 1987;10(5 suppl B):33B–39B
   PubMedGoogle Scholar
• . Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2(8607):349–360
   PubMed Web of Science ®Google Scholar
• . Sabatine MS, Cannon CP, Gibson CM, ; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179–1189
   PubMed Web of Science ®Google Scholar
• . Chen ZM, Jiang LX, Chen YP, ; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2006;366(9497):1607–1621
   Google Scholar
• . Gold HK, Fallon JT, Yasuda T, . Coronary thrombolysis with recombinant human tissue-type plasminogen activator. Circulation. 1984;70(4):700–707
   PubMedGoogle Scholar
• . The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study group. N Engl J Med. 1985;312(14):932–936
   PubMed Web of Science ®Google Scholar
• . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Eng J Med. 1993;329(10):673–682
   PubMed Web of Science ®Google Scholar
• . Gibson CM, Cannon CP, Greene RM, . Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial. Am J Cardiol. 1997;80(1):21–26
   PubMedGoogle Scholar
• . Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361(9351):13–20
   PubMed Web of Science ®Google Scholar
• . Widimsky P, Budesínsk$yA T, Vorác D, ; PRAGUE Study Group Investigators. Long distance transport for primary angioplasty vs immediate thromboylsis in acute myocardial infarction. Final results of the randomized national mulitcentre trial—PRAGUE-2. Eur Heart J. 2003;24(1):94–104
   PubMed Web of Science ®Google Scholar
• . Andersen HR, Nielsen TT, Vesterlund T, ; DANAMI-2 Investigators. Danish multicenter randomized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction: rationale and design of the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2). Am Heart J. 2003;146(2):234–241
   PubMedGoogle Scholar
• . Brar SS, Leon MB, Stone GW, . Use of drag-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol. 2009;53(18):1677–1689
   PubMedGoogle Scholar
• . Stone GW, Rizvi A, Newman W, ; SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362(18):1663–1674
   PubMed Web of Science ®Google Scholar
• . Kedhi E, Joesoef KS, McFadden E, . Second-generation everolimus-eluting and paclitaxel-eluting stents in real life practice (COMPARE):a randomised trial. Lancet. 2010;375(9710):201–209
   PubMed Web of Science ®Google Scholar
• . Serruys PW, Silber S, Garg S, . Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363(2):136–146
   PubMed Web of Science ®Google Scholar
• . Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drag eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119(12):1056–1061
   PubMed Web of Science ®Google Scholar
• . Levine GN, Bates ER, Blankenship JC, . 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124(23)e574–e651
   PubMed Web of Science ®Google Scholar
• . Hagi C, Khaladj N, Peterss S, . Acute treatment of ST-segment-elevation myocardial infarction: is there a role for the cardiac surgeon? Ann Thorac Surg. 2009;88(6):1786–1792
   PubMedGoogle Scholar
• . Hlatky MA, Boothroyd DB, Bravata DM, . Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet. 2009;373(9670):1190–1197
   PubMed Web of Science ®Google Scholar
• . Daemen J, Boersma E, Flather M, . Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation. 2008;118(11):1146–1154
   PubMed Web of Science ®Google Scholar
• . Svilaas T, Vlaar PJ, van der Horst IC, . Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358(6):557–567
   PubMed Web of Science ®Google Scholar
• . Vlaar PJ, Svilaas T, van der Horst IC, . Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS):a 1-year follow-up study. Lancet. 2008;371(9628):1915–1920
   PubMed Web of Science ®Google Scholar
• . Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S. Unfractionated and low-molecular weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation myocardial infarction: a meta-analysis of the randomized trials. Circulation. 2005;112(25):3855–3867
   PubMed Web of Science ®Google Scholar
• . Yusuf S, Mehta SR, Chrolavicius S, ; OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;95(13):1519–1530
   Google Scholar
• . Sejersten M, Nielsen SL, Engstrøm T, Jørgensen E, Clemmensen P. Feasibility and safety of prehospital administration of bivaliradin in patients with ST-elevation myocardial infarction. Am J Cardiol. 2009;103(12):1635–1640
   PubMedGoogle Scholar
• . Stone GW, Witzenbichler B, Guagliumi G, . Bivaliradin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218–2230
   PubMed Web of Science ®Google Scholar
• . Gurbel PA, Bliden KP, Butler K, . Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120(25):2577–2585
   PubMed Web of Science ®Google Scholar
• . Storey RF. New P2Y12 inhibitors. Heart. 2011;97(15):1262–1267
   PubMedGoogle Scholar
• . Bonello L, Tantry US, Marcucci R, ; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919–933
   PubMed Web of Science ®Google Scholar
• . Asai F, Jakubowski JA, Naganuma H, . Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. Platelets. 2006;17(4):209–217
   PubMed Web of Science ®Google Scholar
• . Wiviott SD, Braunwald E, McCabe CH, ; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015
   PubMed Web of Science ®Google Scholar
• . Montalescot G, Wiviott SD, Braunwald E, ; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373(9665):723–731
   PubMed Web of Science ®Google Scholar
• . Wallentin L, Becker RC, Budaj A, ; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057
   PubMed Web of Science ®Google Scholar
• . Steg PG, James S, Harrington RA, ; PLATO Study Group. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010;122(21):2131–2141
   PubMed Web of Science ®Google Scholar
• . Stenestrand U, Wallentin L; Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001;285(4):430–436
   PubMed Web of Science ®Google Scholar
• . Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C; TNT Steering Committee Members and Investigators. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol. 2004;93(2):154–158
   PubMedGoogle Scholar
• . Cannon CP, Braunwald E, McCabe CH, ; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–1504
   PubMed Web of Science ®Google Scholar
• . Ray KK, Cannon CP, McCabe CH, ; PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005;46(8):1405–1410
   PubMedGoogle Scholar
• . Schwartz GG, Olsson AG, Ezekowitz MD, . Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–1718
   PubMed Web of Science ®Google Scholar
• . Pedersen TR, Faergeman O, Kastelein JJ, ; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437–2445
   PubMed Web of Science ®Google Scholar
• . Held P, Yusuf S. Early intravenous beta-blockade in acute myocardial infarction. Cardiology. 1989;76(2):132–143
   PubMedGoogle Scholar
• . Califf RM, Lokhnygina Y, Velazquez EJ, . Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). Am J Cardiol. 2009;104(2):151–157
   PubMedGoogle Scholar
• . Rutherford JD, Pfeffer MA, Moyé LA, . Effects of Captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation. 1994;90(4):1731–1738
   PubMedGoogle Scholar
• . ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345(8951):669–685
   PubMed Web of Science ®Google Scholar
• . Siqurdsson A, Swedberg K. Left ventricular remodelling, neurohormonal activation and early treatment with enalapril (CONSENSUS II) following myocardial infarction. Eur Heart J. 1994;15( suppl B):14–19
   Google Scholar
• . GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet. 1994;343(8906):1115–1122
   PubMed Web of Science ®Google Scholar
• . Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet. 1995;345(8951):686–687
   PubMedGoogle Scholar
• . Borghi C, Ambrosioni E; Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am Heart J. 2007;153(3):e7–e14
   PubMedGoogle Scholar
• . Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation. 1998;97(22):2202–2212
   PubMed Web of Science ®Google Scholar
• . Pfeffer MA, McMurray JJ, Velazquez EJ, ; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893–1906
   PubMed Web of Science ®Google Scholar
• . McNulty PH, King N, Scott S, . Effects of supplemental oxygen administration on coronary blood flow in patients undergoing cardiac catheterization. Am J Physiol Heart Circ Physiol. 2005;288(3):H1057–H1062
   PubMedGoogle Scholar
• . Cabello JB, Burls A, Emparanza JI, Bayliss S, Quinn T. Oxygen therapy for acute myocardial infarction. Cochrane Database Syst Rev. 2010;(6):CD007160
   Google Scholar